Aton Group announces the appointment of Hadrien Lanvin as Deputy CEO. Having served on the group's board since December 2023, Lanvin will assist in enhancing the value of the group's assets, which specialize in life sciences and medical technologies.
Hadrien Lanvin, a graduate of HEC Paris and the founder-CEO of Evora Biosciences, assumes his new role as Deputy CEO of Aton. Serving on the group's board since December 2023, he has gained a deep understanding of the group's assets and their markets through his board involvement.
Primary Mission at Aton
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In his new role, Hadrien Lanvin's main task will be to support the enhancement of Aton Group's asset values by improving the clarity of their strategic positioning, markets, and development prospects. He will work closely with the leadership teams of the subsidiaries to support their growth trajectory and enhance their visibility within the financial and industrial ecosystem.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 0.7M€
EBITDA: -0,1M€
Net income: -1,0M€
3.1M€
Guidance from the release
En 2025, nous avons tenu nos engagements : structure de coûts assainie, filiales en ordre de marche, premiers jalons commerciaux posés.
Le Groupe Aton a réalisé une amélioration relative de la performance opérationnelle.
Risks mentioned
Environnement de financement toujours sélectif pour les sociétés de biotechnologies.
Risque lié à la montée en volumes de production d'anticorps à récepteurs Fc humain.
Opportunities identified
Signature de nouveaux partenariats industriels stratégiques.
Obtention d'un financement de 500 K€ de Bpifrance.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
